Patrys Limited announced it has identified and selected anoptimised stable cell line for production of its full-sized IgG deoxymab, PAT-DX3. This allows the
Company to commence work on developing a commercial scale manufacturing process for GMP-grade
(Good Manufacturing Practice) PAT-DX3 deoxymab that is required to commence its clinical
development.
The establishment of a stable, PAT-DX3-producing cell line is an important milestone that Patrys has
achieved ahead of its scheduled timeline. Patrys has established that the selected cell line is both
stable and able to deliver reproducible and consistent production of PAT-DX3 protein over time. This
cell line will be stored as a Master Cell Bank (MCB) which will form the basis for all future production
of PAT-DX3.
Studies conducted to date have shown that PAT-DX3 is able to cross the blood brain barrier in animal
models of brain cancer and penetrate cancer cells. PAT-DX3 appears to have a higher affinity for DNA
than PAT-DX1, suggesting that it has the potential to be more efficacious. In addition, Patrys has
reported that PAT-DX3 was able to be used as a targeting agent to successfully deliver an anticancer
drug in an animal model of human breast cancer. In view of this potential, the Company is actively
exploring partnering opportunities for PAT-DX3 to be used in antibody drug conjugates (ADCs) for the
targeted intracellular delivery of cancer drugs and a range of other payloads such as nucleic acids.